HUTCHMED Discovers Novel ORPATHYS® and TAGRISSO® Combination for Non‑small Cell Lung Cancer
HUTCHMED has introduced the groundbreaking combination therapy of ORPATHYS® (savolitinib) and TAGRISSO® (osimertinib) for patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) with MET amplification, following disease progression on EGFR inhibitor therapy.
ORPATHYS® is an oral, potent, and highly selective MET tyrosine kinase inhibitor (TKI) that has shown clinical efficacy in advanced solid tumours.
It targets abnormal activation of the MET receptor tyrosine kinase pathway caused by mutations (such as exon 14 skipping alterations or other point mutations), gene amplification, or protein overexpression.
TAGRISSO® (osimertinib), a third-generation EGFR-TKI, effectively treats NSCLC, including cases with CNS metastases. Available in 40 mg and 80 mg tablets, it has benefited nearly 800,000 patients worldwide.
Lung cancer remains the leading cause of cancer-related deaths, accounting for roughly one-fifth of all cancer fatalities. Among lung cancer types, non-small cell lung cancer (NSCLC) constitutes 80–85 percent of cases.
Approximately 75 percent of NSCLC patients are diagnosed at an advanced stage, with EGFR-mutated (EGFRm) NSCLC affecting about 10–15 percent of patients in the US and Europe and 30–40 percent in Asia.
China’s National Medical Products Administration (NMPA) has granted breakthrough therapy designation to the combination of ORPATHYS® and TAGRISSO® for the treatment of certain lung cancer patients following disease progression on EGFR inhibitor therapy.
